Two Routes to a GLP-1 Prescription in Britain: How the NHS Pathway Compares With Going Private
Photo: Mtaylor848, CC BY-SA 4.0, via Wikimedia Commons
For anyone researching prescription weight-loss treatment in the UK, one question tends to surface early: can I get this on the NHS, or will I need to pay privately? The answer matters more than most people expect, because the two routes differ not just in cost but in who qualifies, how long treatment takes to begin, and what support comes with it.
This article explains how each system works, without recommending one over the other. The right route depends on your health, your finances and your priorities — and understanding the trade-offs is the first step.
What NICE Guidance Actually Says
The National Institute for Health and Care Excellence (NICE) has approved two GLP-1 receptor agonists for weight management in recent years. Semaglutide (marketed as Wegovy) was recommended under NICE guidance TA865, and tirzepatide (Mounjaro) followed under TA1026.
Crucially, these recommendations apply to the NHS and come with strict conditions:
- A BMI of 35 or above, with lower thresholds (typically 32.5) considered for people from Black African, Asian or other minority ethnic backgrounds, where weight-related health risks arise at lower BMI levels
- At least one weight-related comorbidity, such as type 2 diabetes, hypertension or obstructive sleep apnoea
- A commitment to use the medication alongside a reduced-calorie diet, physical activity and structured support
- In tirzepatide's case, NICE stipulated use only within specialist weight-management services
Private prescribing is governed differently. Registered UK prescribers can prescribe licensed weight-loss medications off the back of their own clinical judgement and the medicines' marketing authorisation from the MHRA, which permits use at lower BMI thresholds (typically a BMI of 30, or 27 alongside a weight-related condition).
The NHS Route: Thorough but Constrained
NHS access to these medications is channelled through specialist weight-management services — usually multidisciplinary teams including dietitians, psychologists and specialist nurses. Your GP cannot simply write a prescription; they refer you onwards, and the specialist service assesses whether you meet the criteria and whether the medication is clinically appropriate.
The advantages are considerable. Treatment is free at the point of use, clinical oversight is comprehensive, and you are supported by a team rather than a single prescriber. For patients with complex health needs, this depth of care is difficult to replicate.
The constraints, however, are equally real. Specialist weight-management services are commissioned unevenly across England, Wales and Scotland — some integrated care boards fund them generously, others barely at all. Waiting lists for referral and assessment can stretch from several months to, in some areas, years. In practice, many patients who meet NICE criteria find no accessible service in their region, a point frequently raised in parliamentary debates about so-called postcode lotteries.
The Private Route: Faster Access, Meaningful Cost
Private weight-loss clinics — increasingly operating online — have expanded rapidly since semaglutide became available for weight management. These services connect patients with GMC-registered prescribers or pharmacist independent prescribers who assess eligibility through online questionnaires and, in reputable services, video or telephone consultations.
The appeal is straightforward: assessments typically happen within days, and medication can arrive within a week or two of approval. BMI thresholds are often lower, meaning more people qualify.
The costs are substantial, though. Private GLP-1 treatment generally runs from roughly £150 to £300 per month depending on the medication and dose, and NICE's own modelling assumes treatment may continue for years to sustain weight loss. Over a multi-year course, total outlay can run into thousands of pounds — with no NHS subsidy. Patients should also confirm whether consultation fees, delivery and aftercare are included in the advertised price.
Side-by-Side: The Practical Trade-Offs
| Factor | NHS | Private |
|---|---|---|
| Cost | Free (if you can access the service) | Roughly £150–£300+ per month |
| Waiting time | Months to years; availability varies by region | Days to weeks |
| Eligibility threshold | BMI 35+ (or 32.5+ for some ethnic groups) plus comorbidity | Typically BMI 30+, or 27+ with a weight-related condition |
| Prescribing context | Specialist weight-management service | Independent prescriber judgement |
| Support | Multidisciplinary team | Varies by provider — scrutinise carefully |
Which Route Fits Your Circumstances?
There is no universally correct answer. If you have complex health conditions, prefer comprehensive multidisciplinary support, and can tolerate a long wait or live near an accessible service, the NHS pathway merits pursuing — start with a GP appointment and ask specifically about referral to a specialist weight-management service.
If waiting is not viable, or you do not meet NHS thresholds but a lower BMI threshold applies to you, a private clinic may be appropriate — provided you vet the provider rigorously. Registration with the General Pharmaceutical Council or Care Quality Commission, genuine prescriber consultations, and structured aftercare are the non-negotiables. Our companion guide to choosing an online weight-loss clinic covers those checks in detail.
Whichever route you consider, the underlying principle is the same: GLP-1 medications are serious prescription treatments, not lifestyle shortcuts. They work best when combined with dietary and behavioural change, and they require ongoing monitoring. Wherever you obtain your prescription, make sure that monitoring comes with it.
